摘要
breast cancer: breast cancerResistance to endocrine therapy often plays a crucial role in HR+ advanced breast cancer, frequently driven by hyperactivity of cyclin D-cyclin-dependent kinase 46 (CDK4/6). These findings have prompted researchers to explore the potential benefits of treating such cancers with therapies that inhibit CDK4/6 activity. “CDK4/6 inhibitors with endocrine therapy have been shown to improve survival outcomes in pretreated patients with HR+/HER2-advanced breast cancer progressing on endocrine therapy,” said Xu Binghe, MD, at the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College in Beijing. In previous research, the novel CDK4/6 inhibitor dalpiciclib (SHR6390) demonstrated tolerability and preliminary antitumor activity in heavily pretreated HR+/HER2- advanced breast cancer. Binghe and his colleagues expounded the compelling research by conducting DAWNA-1, a randomized, Phase III clinical trial evaluating the effects of dalpiciclib administered with fulvestrant concomitantly in HR+/HER2- advanced breast cancer patients whose cancers had either relapsed or progressed while on previous endocrine therapy. Binghe presented data from DAWNA-1 at the ASCO 2021 Annual Meeting (Abstract 1002). Study Design Abstract 1002 DAWNA enrolled 361 women from 39 centers with HR+/HER2- metastatic or locally advanced breast cancer whose cancer had progressed either during or after receiving endocrine therapy in the adjuvant or metastatic setting. Eligible enrollees had an ECOG PS 0/1 and could not have received more than one previous chemotherapy treatment for advanced cancer. Patients were stratified based on the presence of visceral metastases as well as their menopausal status. “Characteristics were generally balanced between the two groups,” Binghe told ASCO 2021 attendees. “About 60 percent of the study patients had visceral metastases and 45 percent were pre- or peri-menopausal women. The majority of patients had received one prior line of endocrine therapy.” Researchers randomized the 361 patients 2:1 to receive dalpiciclib with fulvestrant [(n=261) dalpiciclib 150 mg orally once daily for 21 days every 4 weeks)] or placebo with fulvestrant [(n=120), (fulvestrant; 500 mg during cycle 1, day 1 and 15 then day 1 every 4 weeks)]. Patients who received dalpiciclib-fulvestrant showed significant improvements in INV-assessed PFS over a median follow-up of 10.5 months compared to the placebo-fulvestrant group (median 15.7 [95% CI 11.1-NR] vs. 7.2 [95% CI 0.31-058]; P <0.0001). The COVID-19 pandemic forced Binghe and his colleagues to adjust their study design. “The initially planned sample size for the study was 288 patients, which provides 90 percent power to detect a hazard ratio of 0.6 for the dalpiciclib group versus the placebo group, with a one-sided significance level of 0.025,” explained Binghe. “With the outbreak of COVID-19 pandemic, we amended the protocol and increased the sample size to 357 patients, based on the recommendations from the Internal Displacement Monitoring Centre.” Research Findings Investigator-assessed progression-free survival (INV-PFS) served as the primary endpoint for DAWNA-1. Secondary endpoints included independent review committee progression-free survival (IRC-PFS), objective response rate (ORR), overall survival (OS), and clinical benefit response (CBR). The median follow-up was ~10.7 months. Binghe and colleagues found that median progression-free survival (PFS) was 15.7 months in the dalpiciclib + fulvestrant arm compared with 7.2 months in the placebo group (HR=0.42, p<0.0001). Based on data collected by the planned cutoff date of November 15, 2020, nearly three-fourths of the projected number of PFS had occurred (71.4%), and investigators had conducted a preplanned interim analysis, which yielded what Binghe referred to as a “one-sided [p-value of] less than 0.008.” “The PFS results based on independent review committee assessment were consistent with the primary analysis, showing a reduction in the risk of progression or death by 55 percent in dalpiciclib group versus the placebo group.” In addition, all indicators of PFS in the subgroups favor the dalpiciclib group over the placebo group. The ORR in the dalpiciclib group versus the placebo group was 27.0 percent versus 20.0 percent. The CBR was 61.0 percent versus 45.8 percent. Similarly, tumor response favored the dalpiciclib combination therapy, as assessed by the independent review committee. Patients in the dalpiciclib arm had similar durations of exposure for both dapiciclib and fulvestrant (9.4 months vs. 9.9 months). The most common grade 3 or 4 adverse events observed were neutropenia (84.2% vs. 0%) and leukopenia (62.1% vs. 0%), and more adverse events were observed in the dalpiciclib group than the placebo group. However, Binghe noted that patients on dalpiciclib therapy who experienced the adverse events generally tolerated them well. In the dalpiciclib arm, 96 patients discontinued treatment due to disease progression (n=83), an adverse event (n=8), patient decision (n=4), or some other reason (n=1). The majority of the 77 patients who discontinued treatment in the placebo arm did so due to disease progression (n=68). Additional reasons patients did not finish the study included an adverse event (n=5), patient decision (n=1), and investigation decision (n=1). Death also precluded 1 patient from continuing the study in the placebo arm. No cause of death was given. Despite facing COVID-19-related challenges, Binghe indicated that the study's findings still yield some clinical significance overall. “This Phase III study met its primary endpoint by demonstrating that dalpiciclib plus fulvestrant significantly improved PFS versus placebo plus fulvestrant,” Xu summarized. “While overall survival data were not mature yet, the benefit of dalpiciclib beyond the initial study treatment was shown with delayed time to first subsequent chemotherapy.” Frieda Wiley is a contributing writer.